Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIB: Placental Transfer of Certolizumab Pegol
NCT02019602Phase 1Completed
- Sponsor
- UCB
- Start
- Jan 2014
- Primary completion
- Oct 2016
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of certolizumab pegol in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), Crohn's disease and 2 more, sponsored by UCB. Primary endpoint: Plasma Concentration of Certolizumab Pegol (CZP) in the Infant(s) at Birth at Day 0. Started Jan 2014; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)Crohn's diseasepsoriatic arthritis (PsA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02019602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019602.